非谷浓度阿达木单抗和培塞利珠单抗药物水平与依从性良好的类风湿关节炎患者EULAR治疗反应相关
前瞻性观察研究纳入475例类风湿关节炎患者(培塞利珠单抗192例、阿达木单抗283例),在基线及3、6、12个月评估28关节DAS、自报依从性和血清药物水平。完全依从的EULAR良好反应者中位药物水平显著高于非/中度反应者;3个月非谷浓度阿达木单抗切点7.5 mg/L(特异性39.1%、敏感性80.9%)、培塞利珠单抗切点26.0 mg/L(特异性43.9%、敏感性77.8%)可能有助于临床实践。
要点
- 完全依从的EULAR良好反应者中位阿达木单抗/培塞利珠单抗血清药物水平显著高于非/中度反应者(P=0.04和P=0.0005)。
- 3个月非谷浓度阿达木单抗判别良好vs非/中度反应的AUC为0.63(95%CI 0.52, 0.75),切点7.5 mg/L特异性39.1%、敏感性80.9%。
- 3个月非谷浓度培塞利珠单抗判别良好vs非/中度反应的AUC为0.65(95%CI 0.51, 0.78),切点26.0 mg/L特异性43.9%、敏感性77.8%。
核心结论
- 在完全依从的患者中,良好反应者检测到更高的血清药物水平,提示旨在提高血清药物水平的干预(如鼓励依从)可能改善治疗反应。
- 3个月非谷浓度血清药物水平切点阿达木单抗7.5 mg/L和培塞利珠单抗26.0 mg/L可能有助于临床实践。
研究设计与样本
- 前瞻性观察研究,纳入475例类风湿关节炎患者,接受培塞利珠单抗(n=192)或阿达木单抗(n=283)治疗。
- 在基线及3、6、12个月评估28关节DAS、自报治疗依从性和血清药物水平,完全依从患者作为亚组分析,3、6、12个月随访数据分别分析。
主要发现
- 完全依从的良好反应者中位阿达木单抗血清药物水平显著高于非/中度反应者(P=0.04)。
- 完全依从的良好反应者中位培塞利珠单抗血清药物水平显著高于非/中度反应者(P=0.0005)。
- 3个月非谷浓度阿达木单抗血清药物水平判别良好vs非/中度反应的AUC为0.63(95%CI 0.52, 0.75)。
- 3个月非谷浓度培塞利珠单抗血清药物水平判别良好vs非/中度反应的AUC为0.65(95%CI 0.51, 0.78)。
关键数值与推荐
- 3个月非谷浓度阿达木单抗切点7.5 mg/L判别良好vs非/中度反应,特异性39.1%、敏感性80.9%。
- 3个月非谷浓度培塞利珠单抗切点26.0 mg/L判别良好vs非/中度反应,特异性43.9%、敏感性77.8%。
临床怎么用
- 作者认为,在完全依从的患者中,3个月非谷浓度阿达木单抗7.5 mg/L和培塞利珠单抗26.0 mg/L切点可能有助于临床实践。
- 作者认为,提高血清药物水平的干预(如鼓励依从)可能改善治疗反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Interventions aimed at increasing TNF-α inhibitor serum drug levels (SDLs) may improve treatment response; however, previous studies suggesting SDL cut-offs have not accounted for treatment adherence. The aim of this study was to establish the relationship between adalimumab/certolizumab SDLs and EULAR good vs non-/moderate response and to define SDL cut-offs associated with good response in fully adherent patients. METHODS: In a prospective observational study, 475 patients with RA were treated with certolizumab (n = 192) or adalimumab (n = 283). At baseline and 3, 6 and 12 months, patients had 28-joint DAS, self-reported treatment adherence and SDLs measured. Fully adherent patients were analysed as a subgroup. Follow-up data at 3, 6 and 12 months were analysed separately. Median SDLs were compared in good vs non-/moderate response patients and receiver operating characteristics (ROC) curves were used to establish cut-off SDLs. RESULTS: Fully adherent good responders had significantly higher median adalimumab/certolizumab SDLs compared with non-/moderate responders (P = 0.04 and P = 0.0005, respectively). ROC analysis reported 3 month non-trough adalimumab SDLs discriminated good vs non-/moderate response with an area under the curve (AUC) of 0.63 (95% CI 0.52, 0.75), with a cut-off of 7.5 mg/l being 39.1% specific and 80.9% sensitive. Similarly, 3 month non-trough certolizumab SDLs discriminated good vs non-/moderate response with an AUC of 0.65 (95% CI 0.51, 0.78), with a cut-off of 26.0 mg/l being 43.9% specific and 77.8% sensitive. CONCLUSION: In fully adherent patients, higher SDLs are detected in good responders, suggesting that interventions to improve SDLs, such as encouraging adherence, could improve treatment response. The 3 month non-trough SDL cut-offs of 7.5 mg/l for adalimumab and 26.0 mg/l for certolizumab may be useful in clinical practice.
引用
- Hum RM, Ho P, Nair N, et al. Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis. Rheumatology (Oxford). 2023. PMID: 36190343. doi:10.1093/rheumatology/keac564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。